RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing
Vikingsson, S., Hart, E. D., Winecker, R. E., Cone, E. J., Kuntz, D. J., Clark, M., Jacques, M., Hayes, E. D., & Flegel, R. R. (2023). Prevalence of ∆8-tetrahydrocannabinol carboxylic acid in workplace drug testing. Journal of Analytical Toxicology, (8). https://doi.org/10.1093/jat/bkad068
Δ8-Tetrahydrocannabinol (Δ8-THC) recently became widely available as an alternative to cannabis. Δ8-THC is likely impairing and poses a threat to workplace and traffic safety. In the present study the prevalence of Δ8-THC in workplace drug testing was investigated by analyzing 1,504 urine specimens with a positive immunoassay cannabinoid initial test using an LC-MS-MS method quantifying 15 cannabinoid analytes after hydrolysis. Δ8-tetrahydrocannabinol-9-carboxylic acid (Δ8-THC-COOH) was detected in 378 urine specimens (15 ng/mL cutoff), compared to 1,144 specimens containing Δ9-THC-COOH. The data could be divided into three general groups. There were 964 (76%) Δ9-THC-COOH dominant (<10% Δ8-THC-COOH) and 139 (11%) Δ8-THC-COOH dominant (>90% Δ8-THC-COOH) specimens, with the remaining 164 (13%) specimens showing a mixture of both analytes (>90% Δ8-THC-COOH). Similar concentrations of Δ9-THC-COOH (median 187 ng/mL) and Δ8-THC-COOH (150 ng/mL) as the dominant species support the use of similar cutoffs and decision rules for both analytes. Apart from the carboxylic acid metabolites, 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-Δ9-THC, n = 1,282), Δ9-tetrahydrocannabivarin-9-carboxylic acid (Δ9-THCV-COOH, n = 1,058), Δ9-THC (n = 746) and 7-hydroxy-cannabidiol (7-OH-CBD, n = 506) were the most prevalent analytes. Two specimens (0.13%) contained ≥140 ng/mL Δ9-THC without Δ9-THC-COOH, which could be due to genetic variability in the drug metabolizing enzyme CYP2C9 or an adulterant targeting Δ9-THC-COOH. The cannabinoid immunoassay was repeated, and five specimens (0.33%) generated negative initial tests despite Δ9-THC-COOH concentrations of 54-1,000 ng/mL, potentially indicative of adulteration. The use of Δ8-THC is widespread in the US populations, and all forensic laboratories should consider adding Δ8-THC and/or Δ8-THC-COOH to their scope of testing. Similar urinary concentrations were observed for both analytes indicating that the decision rules used for Δ9-THC-COOH are appropriate also for Δ8-THC-COOH.